177 related articles for article (PubMed ID: 23720164)
1. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
Soper MS; Iganej S; Thompson LD
Head Neck; 2014 Jan; 36(1):E4-7. PubMed ID: 23720164
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
Yamamoto N; Minami S; Fujii M
Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
[TBL] [Abstract][Full Text] [Related]
4. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Fushimi C; Tada Y; Takahashi H; Nagao T; Ojiri H; Masubuchi T; Matsuki T; Miura K; Kawakita D; Hirai H; Hoshino E; Kamata S; Saotome T
Ann Oncol; 2018 Apr; 29(4):979-984. PubMed ID: 29211833
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
[TBL] [Abstract][Full Text] [Related]
6. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
[No Abstract] [Full Text] [Related]
8. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
9. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Jeong ISD; Moyers J; Thung I; Thinn MM
Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Boon E; van Boxtel W; Buter J; Baatenburg de Jong RJ; van Es RJJ; Bel M; Fiets E; Oosting SF; Slingerland M; Hoeben A; Tesselaar MET; Jonker MA; Flucke UE; ; van der Graaf WTA; van Herpen CML
Head Neck; 2018 Mar; 40(3):605-613. PubMed ID: 29272069
[TBL] [Abstract][Full Text] [Related]
11. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
12. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
Locati LD; Perrone F; Cortelazzi B; Imbimbo M; Bossi P; Potepan P; Civelli E; Rinaldi G; Quattrone P; Licitra L; Pilotti S
Cancer Biol Ther; 2014 Jun; 15(6):678-82. PubMed ID: 24618694
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
14. [Effective treatment by both anti-androgen therapy and chemotherapy for a patient with advanced salivary duct carcinoma].
Kuroda H; Sakurai T; Yamada M; Uemura N; Ono M; Abe T; Fujii S; Maeda M; Kohda K; Obata M; Ando M; Iyama S; Kato J
Gan To Kagaku Ryoho; 2011 Apr; 38(4):627-30. PubMed ID: 21498992
[TBL] [Abstract][Full Text] [Related]
15. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
[TBL] [Abstract][Full Text] [Related]
16. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
17. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Solberg A; Haugen OA; Viset T; Bergh A; Tasdemir I; Ahlgren G; Widmark A; Angelsen A
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):55-61. PubMed ID: 20598453
[TBL] [Abstract][Full Text] [Related]
18. Duration of androgen suppression in the treatment of prostate cancer.
Bolla M; de Reijke TM; Van Tienhoven G; Van den Bergh AC; Oddens J; Poortmans PM; Gez E; Kil P; Akdas A; Soete G; Kariakine O; van der Steen-Banasik EM; Musat E; Piérart M; Mauer ME; Collette L;
N Engl J Med; 2009 Jun; 360(24):2516-27. PubMed ID: 19516032
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone in metastatic salivary duct carcinoma.
Urban D; Rischin D; Angel C; D'Costa I; Solomon B
J Natl Compr Canc Netw; 2015 Mar; 13(3):288-90. PubMed ID: 25736005
[TBL] [Abstract][Full Text] [Related]
20. Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature.
Poxleitner P; Shoumariyeh K; Steybe D; Hupfer V; Voss PJ; Rawluk J; Ermer M; Miething C; Schmelzeisen R; Duyster J
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):599-603. PubMed ID: 31904529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
